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Abstract: Avian influenza (AI) occurs worldwide and causes tremendous economic losses. The disease is characterised
by respiratory signs, depression, and reduced food and water intake. In the present study, an oil-based vaccine was
prepared by using by using Montanide ISA 70 MVG, was prepared and the duration of immunity checked at different
time intervals. For this purpose, the cumulative mean titre (CMT) was calculated after employing haemagglutination
inhibition test in 50 pullets at day zero before vaccination and then inoculated 0.3 mL of emulsified vaccine
subcutaneously in 40 birds while 10 birds were kept non-vaccinated as a control group throughout the experiment.
On day 21, a booster dose of 0.5 mL emulsified AI vaccine was injected into the vaccinated birds that produced highest
CMT at day 63 and maintained the protective antibody titre on day 84, 105, 126, 152, 182, and 228 in layers. The study
showed that a booster dose at day 21 produced a high protective AI antibody titre in birds that minimises the stress of
repeated shots of aqueous vaccine.
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Introduction
Avian influenza is an infectious viral disease that
affects poultry, caused by type A influenza virus
belonging to the family orthromyxoviridae, genus
influenza virus A. The disease is characterised by
respiratory signs, depression, and reduced feed and
water intake. In egg laying birds, there is a decline in
egg production and quality (1). The financial losses
due to an epidemic of avian influenza can be huge
and management of outbreaks by stamping policy
and pre-emptive culling policy alone leads to very
high cost and economic losses for the public sector,
the industry and ultimately for consumers (2).

In Pakistan, the disease was first reported in
breeder flocks around Rawalpindi/Islamabad during
November 1994 and caused heavy losses up to mid
1995 (3). Avian influenza is an important zoonotic
disease. In addition to the poultry outbreaks, 241
human infections with H5N1 were confirmed, out of
which 141 were fatal as reported by the World Health
Organization (4).
Vaccination is an effective way of controlling
infectious diseases and has achieved spectacular
success in promoting human and animal welfare
(5). During the outbreak of bird flu disease in
northern areas of Pakistan, the Veterinary Research
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In the present study, the duration of immunity
against avian influenza (H5N1) disease was reported at
different time intervals following the administration
of oil-based (Montanide ISA 70 MVG) avian
influenza vaccine in birds.
Materials and methods
Virus and vaccine
Avian influenza virus sub-type H5N1 (A/
Chicken/NARC/2238/06) was obtained from the
Ministry of Forestry, Agriculture and Livestock
(MINFAL) in Islamabad, Pakistan. The virus was
propagated on 10-day-old embryonated chicken
eggs. Chorioallantoic fluid (CAF) was harvested and
formalised. One batch of avian influenza oil-based
vaccine was prepared after conducting all quality
tests as described in OIE terrestrial manual (6).
Experimental design
Fifty pullets of 6 weeks of age were procured from
the poultry unit section of the Veterinary Research
Institute in Lahore. Emulsified vaccine (0.3 mL)
was inoculated subcutaneously to 40 pullets while
10 birds were kept as non-vaccinated controls in
a separate compartment. A booster dose of 0.5 mL
was given to all vaccinated birds after 3 weeks. All
birds were kept under observation for 228 days and
provided with balanced feed.
Serology
Before vaccination, antibody titre was checked
against avian influenza virus. After vaccination,
serum sample were collected on days 21, 42, 63,
84, 105, 126, 152, 182, and 228 and cumulative
mean titre (CMT) were calculated by employing a
haemagglutination inhibition (HI) test (7).
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Results
In process of vaccine
The safety and sterility of prepared avian influenza
oil-based vaccine were satisfactory. All the birds
remained apparently healthy without any adverse
reaction and signs of illness from the immunisation
oil-based AI vaccine.
Serology
On day zero, all 40 birds were inoculated with
oil-based avian influenza at the dose rate of 0.3 mL
subcutaneously. The cumulative mean titre (CMT)
was calculated after employing a HI test; it was 3.56
on day 21.
A booster dose of 0.5 mL was injected into the
vaccinated birds on day 21 and CMT was calculated
on day 42, 63, 84, 105, 126, 152, 182, and 228; the
results were 8.25, 8.82, 7.12, 6.86, 6.13, 5.92, 5.86, and
5.73, respectively. After the booster dose, CMT was
increased on day 42 and it was at its peak on day 63.
After that CMT was gradually decreased and on day
228 it was 5.73 (Figure).
Discussion
Vaccination is part and parcel of good husbandry
and management. In the present study, the duration
of immunity against oil-based avian influenza (H5N1)
vaccine was reported. Numerous experimental
studies using vaccine against H5N1 highly pathogenic
avian influenza (HPAI) have demonstrated the value
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Institute in Lahore prepared an aqueous vaccine
on a war footing basis that effectively controlled
the disease. However, due to quick absorption and
shorter duration of immunity by aqueous vaccine,
there was a need to prepare an oil-based vaccine
that would enhance immunity and minimise the
stress caused to the birds by repeated shots of
aqueous vaccine.
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Figure. Cumulative mean titre (CMT) by haemagglutination
inhibition test for the duration of avian influenza H5N1
vaccine at different time intervals.
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of vaccination in protecting poultry from disease in
minimising virus excretion (8,9).
There is limited published literature regarding
the duration of oil-based avian influenza vaccine in
birds. The present study has revealed the protection
vaccination gives against avian influenza disease. A
similar study was conducted by Stone (10) that used
0.5 mL of vaccine and concluded that there was 90%100% protection in the vaccinated broiler against
death and morbidity. The same author also reported
maximum geometric mean titre (GMT) in layers i.e.
1:597 by 2 consecutive doses of vaccines in layers and
1:422 by 1 dose. This study is in agreement with the

present study, which concluded that a booster dose
of oil-vaccine increased the duration of immunity.
Similarly, Hwang et al. (11) immunized chickens
with oil-adjuvant inactivated H5N1 vaccine, which
protected from lethal infection by highly pathogenic
H5N1 influenza virus until 12 weeks.
In conclusion, a booster dose of Montanide ISA
70 MVG based vaccine on day 21 produced high
protective antibody titre in birds, which maintained
the protective antibody titre for long interval in layers
and reduced the stress of repeated shots of aqueous
vaccine in breeder flock.
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